References
1. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386:983-994.
2. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol
Sci. 2019;20:1475.
3. Takeshita J, Grewal S, Langan SM, Nehta NN, Van Voorhees AS, et al.
Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol.
2017;76:377-390.
4. Springate DA, Parisi R, Kontopantelis E, Reeves D, Ashcroft DM.
Incidence, prevalence and mortality of patients with psoriasis: a U.K.
population-based cohort study. Br J Dermatol. 2017;176:650-658.
5. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of
plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J
Clin Invest. 1994;93:1288-1292.
6. van Eijk M, van Roomen CP, Renkema GH, Bussink AP, Andrews L,
Blommaart EFC, et al. Characterization of human phagocyte-derived
chitotriosidase, a component of innate immunity. Int Immunol.
2005;17:1505-1512.
7. Boot RG, Renkema GH, Strijland A, van Zonneveld AJ, Aerts JM. Cloning
of a cDNA encoding chitotriosidase, a human chitinase produced by
macrophages. J Biol Chem. 1995;270:26252-26256.
8. Malaguarnera L. Chitotriosidase: the yin and yang. Cell Mol Life Sci.
2006;63:3018-3029.
9. Turan E, Sozmen B, Eltutan M, Sozmen EY. Serum chitotriosidase enzyme
activity is closely related to HbA1c levels and the complications in
patients with diabetes mellitus type 2. Diabetes Metab Syndr. 2017;11
Suppl 1:S503-S506.
10. Bennett D, Cameli P, Lanzarone N, Carobene L, Bianchi N, Fui A et
al. Chitotriosidase: a biomarker of activity and severity in patients
with sarcoidosis [published correction appears in Respir Res. 2020 Jan
29;21(1):34]. Respir Res. 2020;21:6.
11. Yildiz BS, Barutcuoglu B, Alihanoglu YI, Alkan MB, Bilgin M, Gul I,
et al. Serum chitotriosidase activity in acute coronary syndrome. J
Atheroscler Thromb. 2013;20:134-141.
12. Thein MS, Kohli A, Ram R, Ingaramo MC, Jain A, Fedarko NS.
Chitotriosidase, a marker of innate immunity, is elevated in patients
with primary breast cancer. Cancer Biomark. 2017;19:383-391.
13. Kologlu T, Ucar SK, Levent E, Akcay YD, Coker M, Sozmen EY.
Chitotriosidase as a possible marker of clinically evidenced
atherosclerosis in dyslipidemic children. J Pediatr Endocrinol Metab.
2014;27:701-708.
14. Boot RG, Blommaart EF, Swart E, Ghauharali-van der Vlugt K, Bijl N,
Moe C, et al. Identification of a novel acidic mammalian chitinase
distinct from chitotriosidase. J Biol Chem. 2001;276:6770-6778.
15. Artieda M, Cenarro A, Gañán A, Jericó I, Gonzalvo C, Casado JM, et
al. Serum chitotriosidase activity is increased in subjects with
atherosclerosis disease. Arterioscler Thromb Vasc Biol.
2003;23:1645-1652.
16. Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol
Clin. 2015;33:13-23.
17. Reich K. The concept of psoriasis as a systemic inflammation:
implications for disease management. J Eur Acad Dermatol Venereol.
2012;26 Suppl 2:3-11.
18. James W BT, Elston D. Errors in metabolism. In: Andrews’ Diseases of
the Skin Clinical Dermatology, 11th ed, James W, Berger T, Elston D
(Eds), Saunders Elsevier, Philadelphia 2011. p.506. In: James W BT,
Elston D. , editor. Andrews’ Diseases of the Skin Clinical Dermatology.
11 ed. Philadelphia Saunders Elsevier; 2011. p. 506.
19. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CEM, Nast A, et
al. Definition of treatment goals for moderate to severe psoriasis: a
European consensus. Arch Dermatol Res. 2011;303:1-10.
20. Ma C, Harskamp CT, Armstrong EJ, Armstrong AW. The association
between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol.
2013;168:486-495.
21. Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC. Lipid
disturbances in psoriasis: an update. Mediators Inflamm. 2010
;2010:535612.
22. Amin M, Lee EB, Tsai TF, Wu JJ. Psoriasis and Co-morbidity. Acta
Derm Venereol. 2020;100:adv00033.
23. Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN, et al.
Psoriasis and systemic inflammatory diseases: potential mechanistic
links between skin disease and co-morbid conditions [published
correction appears in J Invest Dermatol. 2010 Oct;130 :2517.
24. Sonmez A, Haymana C, Tapan S, Safer U, Celebi G, Ozturk O, et al.
Chitotriosidase activity predicts endothelial dysfunction in type-2
diabetes mellitus. Endocrine. 2010;37:455-459.
25. Justin Rucker A, Crowley SD. The role of macrophages in hypertension
and its complications. Pflugers Arch. 2017;469:419-430.
26. Ma WH, Wang XL, Du YM, Wang YB, Zhang Y, Wei DE, et al. Association
between human cartilage glycoprotein 39 (YKL-40) and arterial stiffness
in essential hypertension. BMC Cardiovasc Disord. 2012;12:35.